Molecular and Immunohistochemical Markers with Prognostic and Predictive Significance in Liver Metastases from Colorectal Carcinoma

被引：13

作者：

Lopez, Gianluca ^{[1
]}

Boggio, Francesca ^{[1
]}

Ferrero, Stefano ^{[1
,2
]}

Fusco, Nicola ^{[1
,2
]}

Del Gobbo, Alessandro ^{[1
]}

机构：

[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Pathol, Via Francesco Sforza 35, I-20122 Milan, Italy

[2] Univ Milan, Dept Biomed Surg & Dent Sci, Via Francesco Sforza 35, I-20122 Milan, Italy

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2018年 / 19卷 / 10期

关键词：

biomarkers; immunohistochemistry; molecular markers; colorectal cancer; liver metastases; prognostic; predictive; FOLATE RECEPTOR-ALPHA; CANCER PATIENTS; POOR-PROGNOSIS; CLINICAL-SIGNIFICANCE; BRAF MUTATIONS; PRIMARY TUMORS; BETA-CATENIN; COLON-CANCER; TGF-BETA; C-MET;

D O I：

10.3390/ijms19103014

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Despite the significant recent achievements in the diagnosis and treatment of colorectal cancer (CRC), the prognosis of these patients has currently plateaued. During the past few years, the opportunity to consider multiple treatment modalities (including surgery and other locoregional treatments, systemic therapy, and targeted therapy) led to the research of novel prognostic and predictive biomarkers in CRC liver metastases (CRCLM) patients. In this review, we seek to describe the current state of knowledge of CRCLM biomarkers and to outline impending clinical perspectives, in particular focusing on the cutting-edge tools available for their characterization.

引用

页数：18

共 111 条

[81]

Richman SD, 2011, ANAL CELL PATHOL, V34, P61, DOI [10.1155/2011/393521, 10.3233/ACP-2011-0005]

[82] Endoglin for Targeted Cancer Treatment [J].

Rosen, Lee S. ;

Gordon, Michael S. ;

Robert, Francisco ;

Matei, Daniela E. .

CURRENT ONCOLOGY REPORTS, 2014, 16 (02)

[83] BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection [J].

Schirripa, M. ;

Bergamo, F. ;

Cremolini, C. ;

Casagrande, M. ;

Lonardi, S. ;

Aprile, G. ;

Yang, D. ;

Marmorino, F. ;

Pasquini, G. ;

Sensi, E. ;

Lupi, C. ;

De Maglio, G. ;

Borrelli, N. ;

Pizzolitto, S. ;

Fasola, G. ;

Bertorelle, R. ;

Rugge, M. ;

Fontanini, G. ;

Zagonel, V. ;

Loupakis, F. ;

Falcone, A. .

BRITISH JOURNAL OF CANCER, 2015, 112 (12) :1921-1928

[84]

Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO

[85]

2-9

[86] An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab [J].

Sclafani, Francesco ;

Rimassa, Lorenza ;

Colombo, Piergiuseppe ;

Destro, Annarita ;

Stinco, Sergio ;

Lutman, Fabio R. ;

Carnaghi, Carlo ;

Beretta, Giordano ;

Zanello, Alessandro ;

Roncalli, Massimo ;

Giordano, Laura ;

Santoro, Armando .

INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2015, 30 (01) :E73-E80

[87] Clinicopathological and Prognostic Value of MicroRNA-21 and MicroRNA-155 in Colorectal Cancer [J].

Shibuya, Hajime ;

Iinuma, Hisae ;

Shimada, Ryu ;

Horiuchi, Atsushi ;

Watanabe, Toshiaki .

ONCOLOGY, 2010, 79 (3-4) :313-320

[88] Cancer Statistics, 2012 [J].

Siegel, Rebecca ;

Naishadham, Deepa ;

Jemal, Ahmedin .

CA-A CANCER JOURNAL FOR CLINICIANS, 2012, 62 (01) :10-29

[89] Galectin-3 in cancer [J].

Song, Lin ;

Tang, Jian-wu ;

Owusu, Lawrence ;

Sun, Ming-Zhong ;

Wu, Jun ;

Zhang, Jun .

CLINICA CHIMICA ACTA, 2014, 431 :185-191

[90]

Thanki Ketan, 2017, Int Biol Biomed J, V3, P105

← 3 4 5 6 7 8 9 10 11 12 →